Heavy documents issued, pharmaceutical companies with gold sales and by the bottom of the kettle draw

Pharmaceutical Network Industry Dynamics Recently, the State issued the Guidance on Accelerating the Innovation and Development of Medical Education.
, which put forward the requirements for the credit certification of continuing medical education and the promotion of the innovation and development of continuing medical education.
Among them, it is worth noting that, in accordance with the requirements, medical personnel to continue medical education will be included in the annual quarterly assessment, in terms of funding, employers need to increase investment, according to the law to extract and use staff education funds, in the evaluation of the title of health professional and technical personnel, we must highlight the character, ability and performance-oriented, emphasizing clinical practice and other business ability, breaking the paper-only tendency.
In this regard, the industry believes that in the medical staff's continuing education and evaluation of the title of the great changes, the past has been criticized for the use of academic conferences, sponsorships, donations, bribery, as well as paper fraud, writing, hair and other chaos, as well as pharmaceutical companies with gold sales behavior will lose the living space.
fact, the pharmaceutical industry with gold sales and other persistent diseases have a long history, there have been many medical institutions or their staff for receiving "kickbacks" by the media and the public attention.
in the view of the industry, the long-term existence of the medical field of the act of disrepentment, to a large extent, is due to the lack of institutional constraints, the cost of failure of trust is too low, the punishment for the act of disrepentment is not in place and other reasons.
present, China's pharmaceutical industry is in a critical period of transformation and upgrading, in innovation, quality and compliance has become the main theme of the development of the pharmaceutical industry, in recent years, the state began to step up efforts to combat illegal and illegal activities in the pharmaceutical industry.
Especially since 2018, when nine ministries, including the National Health Care Commission and the State Health Insurance Administration, jointly issued the "2018 Special Governance Points for Correcting The Wrong Wind in the Field of Pharmaceutical Purchase and Sale and Medical Services", various provinces and cities have issued anti-corruption documents on the purchase and sale of medicines, and the anti-corruption and high-pressure efforts have continued.
Overall, from the 4-plus-seven band procurement, to combat fraud insurance, to DRGs pilot, to join forces with the Ministry of Finance to verify the financial problems of 77 pharmaceutical companies, focusing on sales costs, to the establishment of a disciplinary system, with drug collection, drug price negotiations and other policies, in fact, are the country is committed to the source of the fight against commercial bribery measures taken.
these initiatives also mean that the state is weaving a big network to build the integrity system of China's pharmaceutical market from the source, curb the practice of commercial bribery in medicine, and begin to carry out changes in the field of pharmaceutical bidding and procurement.
this, the industry believes that in a new policy environment, for all enterprises in the pharmaceutical industry, once any non-compliance, is undoubtedly a lightning, or even cut off their own future.
, pharmaceutical companies need to take a long-term plan, layout product lines, seeking the future, but also to always adjust the marketing strategy according to policy changes, with the flow.